Poolbeg Pharma (LON:POLB – Get Free Report) issued its quarterly earnings data on Monday. The company reported GBX (0.43) EPS for the quarter, Digital Look Earnings reports.
Poolbeg Pharma Price Performance
LON POLB opened at GBX 3.71 on Tuesday. The stock’s fifty day moving average price is GBX 3.35 and its 200 day moving average price is GBX 3.12. Poolbeg Pharma has a 1 year low of GBX 2.25 and a 1 year high of GBX 9.60. The company has a market cap of £25.87 million, a price-to-earnings ratio of -319.83 and a beta of 2.11.
Analysts Set New Price Targets
Separately, Shore Capital reiterated a “house stock” rating on shares of Poolbeg Pharma in a report on Friday.
Poolbeg Pharma Company Profile
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).
Featured Articles
- Five stocks we like better than Poolbeg Pharma
- The 3 Best Blue-Chip Stocks to Buy Now
- Qualcomm Is on Its Biggest Uptrend in 2 Years—Can It Continue?
- How to Calculate Return on Investment (ROI)
- Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Cathie Wood Buys Alibaba and Baidu: Momentum or More Value Ahead?
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
